Concepedia

Author

Jifeng Feng

Jiangsu Cancer HospitalORCID

Also Known As

Feng Jifeng, Feng, Ji-Feng, Feng, Jifeng, JI-FENG FENG, Ji-Feng Feng, Ji-feng Feng, Jifeng FENG, Jifeng Feng, Jifeng Feng (432175), Ji‐Feng Feng

494

Publications

33.4K

Citations

63

H-Index

112

Concepts

All Affiliations

Jiangsu Cancer HospitalNanjing Medical UniversityChinese Academy of Medical Sciences & Peking Union Medical CollegeHarbin Medical UniversityThird Affiliated Hospital of Harbin Medical University
JF

About

Jifeng Feng is an author at Jiangsu Cancer Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

41

88

21.1K

2

Health Sciences

14

16

6.8K

3

Engineering

3

3

62

4

Public Health

2

2

48

5

Biostatistics

2

2

39

Jifeng Feng

×

229

Publications

31.6K

Citations

60

H-Index

YearCitations

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen,

The Lancet Oncology

2008

5.8K

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen,

The Lancet Oncology

2011

4K

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba,

The Lancet

2019

3.2K

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen,

The Lancet

2019

2.1K

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu,

The Lancet Oncology

2014

2K

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler,

The Lancet Oncology

2015

1.6K

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen,

The Lancet Oncology

2020

662

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung,

Journal of Clinical Oncology

2014

611

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang,

The Lancet Respiratory Medicine

2020

488

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Caicun Zhou, Yi‐Long Wu, Gongyan Chen,

Journal of Clinical Oncology

2015

381

Page 1